5. Voulvoulis N, Barceló D, Verlicchi P, Pharmaceutical Residues in Sewage Treatment Works
and their Fate in the Receiving Environment, In Pharmaceuticals in the Environment, Hester,
R. E., Harrison, R. M., Eds., Issues in Environmental Science and Technology No. 41, The
Royal Society of Chemistry, 2015, pp 120–179.
6. Jiménez-González C, Constable D. C, Ponder C. S, Evaluating the “greenness” of chemical
processes and products in the pharmaceutical industry–a green metrics primer, Chemical
Society reviews, Vol. 41, No. 4, 2012, pp 1485–1498.
7. Jiménez-González C, Overcash M. R, The evolution of life cycle assessment in pharmaceutical and chemical applications – a perspective, Green Chem., Vol. 16, No. 7, 2014, p 3392.
8. Mata T. M, Martins A. A, Neto B, Martins M. L, Salcedo, R, Costa C, LCA Tool for
Sustainability Evaluations in the Pharmaceutical Industry, Chemical Engineering
Transactions, Vol. 26, 2012.
9. Minkov N, Schneider L, Lehmann A, Finkbeiner M, Type III Environmental Declaration
Programmes and harmonization of product category rules: Status quo and practical
challenges, Journal of Cleaner Production, Vol. 94, 2015, pp 235–246.
10. Wernet G, Conradt S, Isenring H. P, Jiménez-González C, Hungerbühler K, Life cycle
assessment of fine chemical production: A case study of pharmaceutical synthesis, Int J Life
Cycle Assess, Vol. 15, No. 3, 2010, pp 294–303.
11. Jiménez-González C, Ollech C, Pyrz W, Hughes D, Broxterman Q. B, Bhathela N.,
Expanding the Boundaries: Developing a Streamlined Tool for Eco-Footprinting of
Pharmaceuticals, Org. Process Res. Dev., Vol. 17, No. 2, 2013, pp 239–246.
12. Brunet R, Guillén-Gosálbez G, Jiménez L, Combined simulation–optimization methodology
to reduce the environmental impact of pharmaceutical processes: Application to the
production of Penicillin V, Journal of Cleaner Production, Vol. 76, 2014, pp 55–63.
13. De Soete W, Boone L, Willemse F, Meyer E, Heirman B, van Langenhove H, Dewulf J,
Environmental resource footprinting of drug manufacturing: Effects of scale-up and tablet
dosage, Resources, Conservation and Recycling, Vol. 91, 2014, pp 82–88.
14. Kim S, Jiménez-González C, Dale B. E, Enzymes for pharmaceutical applications—a
cradle-to-gate life cycle assessment, Int J Life Cycle Assess, Vol. 14, No. 5, 2009, pp 392–
400.
15. Taggart M. A, Richards N, Kinney C. A, Impacts of Pharmaceuticals on Terrestrial Wildlife,
In Pharmaceuticals in the Environment, Hester, R. E., Harrison, R. M., Eds., Issues in
Environmental Science and Technology No. 41, The Royal Society of Chemistry, 2015,
pp 216–254.
16. Crane M, Watts C, Boucard T, Chronic aquatic environmental risks from exposure to human
pharmaceuticals, Science of the Total Environment, Vol. 367, 2006, pp 23–41.
17. Santos L. H. M. L. M, Araujo A. N, Fachini A, Pena A, Delerue-Matos C, Montenegro M.
C. B. S. M., Ecotoxicological aspects related to the presence of pharmaceuticals in the aquatic
environment, Journal of hazardous materials, Vol. 175, 1–3, 2010, pp 45–95.
18. Alfonsín C, Hospido A, Omil F, Moreira M. T, Feijoo G, PPCPs in wastewater – Update and
calculation of characterization factors for their inclusion in LCA studies, Journal of Cleaner
Production, Vol. 83, 2014, pp 245–255.
19. Ortiz de García S, García-Encina P. A, Irusta-Mata R, The potential ecotoxicological impact
of pharmaceutical and personal care products on humans and freshwater, based on USEtox™
characterization factors. A Spanish case study of toxicity impact scores, The Science of the
total environment, Vol. 609, 2017, pp 429–445.
20. Muñoz I, José Gómez M, Molina-Díaz A, Huijbregts M. A, Fernández-Alba A. R,
García-Calvo E, Ranking potential impacts of priority and emerging pollutants in urban
wastewater through life cycle impact assessment, Chemosphere, Vol. 74, No. 1, 2008,
pp 37–44.
21. Bergman Å, Heindel J. J, Jobling S, Kidd K. A, Zoeller R. T, Eds., State of the Science of
Endocrine Disrupting Chemicals - 2012: An assessment of the state of the science of
endocrine disruptors, WHO; UNEP, 2013.
Life Cycle Management in the Pharmaceutical Industry …
87
and their Fate in the Receiving Environment, In Pharmaceuticals in the Environment, Hester,
R. E., Harrison, R. M., Eds., Issues in Environmental Science and Technology No. 41, The
Royal Society of Chemistry, 2015, pp 120–179.
6. Jiménez-González C, Constable D. C, Ponder C. S, Evaluating the “greenness” of chemical
processes and products in the pharmaceutical industry–a green metrics primer, Chemical
Society reviews, Vol. 41, No. 4, 2012, pp 1485–1498.
7. Jiménez-González C, Overcash M. R, The evolution of life cycle assessment in pharmaceutical and chemical applications – a perspective, Green Chem., Vol. 16, No. 7, 2014, p 3392.
8. Mata T. M, Martins A. A, Neto B, Martins M. L, Salcedo, R, Costa C, LCA Tool for
Sustainability Evaluations in the Pharmaceutical Industry, Chemical Engineering
Transactions, Vol. 26, 2012.
9. Minkov N, Schneider L, Lehmann A, Finkbeiner M, Type III Environmental Declaration
Programmes and harmonization of product category rules: Status quo and practical
challenges, Journal of Cleaner Production, Vol. 94, 2015, pp 235–246.
10. Wernet G, Conradt S, Isenring H. P, Jiménez-González C, Hungerbühler K, Life cycle
assessment of fine chemical production: A case study of pharmaceutical synthesis, Int J Life
Cycle Assess, Vol. 15, No. 3, 2010, pp 294–303.
11. Jiménez-González C, Ollech C, Pyrz W, Hughes D, Broxterman Q. B, Bhathela N.,
Expanding the Boundaries: Developing a Streamlined Tool for Eco-Footprinting of
Pharmaceuticals, Org. Process Res. Dev., Vol. 17, No. 2, 2013, pp 239–246.
12. Brunet R, Guillén-Gosálbez G, Jiménez L, Combined simulation–optimization methodology
to reduce the environmental impact of pharmaceutical processes: Application to the
production of Penicillin V, Journal of Cleaner Production, Vol. 76, 2014, pp 55–63.
13. De Soete W, Boone L, Willemse F, Meyer E, Heirman B, van Langenhove H, Dewulf J,
Environmental resource footprinting of drug manufacturing: Effects of scale-up and tablet
dosage, Resources, Conservation and Recycling, Vol. 91, 2014, pp 82–88.
14. Kim S, Jiménez-González C, Dale B. E, Enzymes for pharmaceutical applications—a
cradle-to-gate life cycle assessment, Int J Life Cycle Assess, Vol. 14, No. 5, 2009, pp 392–
400.
15. Taggart M. A, Richards N, Kinney C. A, Impacts of Pharmaceuticals on Terrestrial Wildlife,
In Pharmaceuticals in the Environment, Hester, R. E., Harrison, R. M., Eds., Issues in
Environmental Science and Technology No. 41, The Royal Society of Chemistry, 2015,
pp 216–254.
16. Crane M, Watts C, Boucard T, Chronic aquatic environmental risks from exposure to human
pharmaceuticals, Science of the Total Environment, Vol. 367, 2006, pp 23–41.
17. Santos L. H. M. L. M, Araujo A. N, Fachini A, Pena A, Delerue-Matos C, Montenegro M.
C. B. S. M., Ecotoxicological aspects related to the presence of pharmaceuticals in the aquatic
environment, Journal of hazardous materials, Vol. 175, 1–3, 2010, pp 45–95.
18. Alfonsín C, Hospido A, Omil F, Moreira M. T, Feijoo G, PPCPs in wastewater – Update and
calculation of characterization factors for their inclusion in LCA studies, Journal of Cleaner
Production, Vol. 83, 2014, pp 245–255.
19. Ortiz de García S, García-Encina P. A, Irusta-Mata R, The potential ecotoxicological impact
of pharmaceutical and personal care products on humans and freshwater, based on USEtox™
characterization factors. A Spanish case study of toxicity impact scores, The Science of the
total environment, Vol. 609, 2017, pp 429–445.
20. Muñoz I, José Gómez M, Molina-Díaz A, Huijbregts M. A, Fernández-Alba A. R,
García-Calvo E, Ranking potential impacts of priority and emerging pollutants in urban
wastewater through life cycle impact assessment, Chemosphere, Vol. 74, No. 1, 2008,
pp 37–44.
21. Bergman Å, Heindel J. J, Jobling S, Kidd K. A, Zoeller R. T, Eds., State of the Science of
Endocrine Disrupting Chemicals - 2012: An assessment of the state of the science of
endocrine disruptors, WHO; UNEP, 2013.
Life Cycle Management in the Pharmaceutical Industry …
87